Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
- First Posted Date
- 2022-05-16
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 47
- Registration Number
- NCT05374603
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Conditions
- Interventions
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 340
- Registration Number
- NCT05361395
- Locations
- 🇺🇸
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Christiana Care Health Services, Newark, Delaware, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
Himalaya Early Access Program
- Conditions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT05345678
- Locations
- 🇺🇸
Research Site, Morgantown, West Virginia, United States
An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC
- Conditions
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 65
- Registration Number
- NCT05327582
- Locations
- 🇨🇳
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 725
- Registration Number
- NCT05301842
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 61
- Registration Number
- NCT05303532
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 784
- Registration Number
- NCT05298423
- Locations
- 🇨🇳
Tianjin Cancer Hospital ( Site 0329), Tianjin, Tianjin, China
🇨🇳Hangzhou Cancer Hospital-Medical Oncology ( Site 0302), Hangzhou, Zhejiang, China
🇨🇳The Second Affiliated hospital of Zhejiang University school of medicine ( Site 0301), Hangzhou, Zhejiang, China
Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy
- Conditions
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2022-03-04
- Target Recruit Count
- 30
- Registration Number
- NCT05267392
- Locations
- 🇵🇹
Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto), Porto, Portugal
Durvalumab (MEDI4736) Plus Platinum-based Chemotherapy in Advanced LCNEC: a Pilot Phase II Study
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Elizabeth Dudnik
- Target Recruit Count
- 22
- Registration Number
- NCT05262985
- Locations
- 🇮🇱
Assuta MC, Tel Aviv, Israel
Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 1615
- Registration Number
- NCT05255653
- Locations
- 🇨🇦
The POLEmut-BLUE trial: Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
🇳🇱Medisch Spectrum Twente, Enschede, Netherlands
🇳🇱The MMRd-GREEN trial: Leiden University Medical Center, Leiden, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.